Fuente: © GlaxoSmithKline
http://www.gsk.com/

Adrian Rawcliffe to lead GlaxoSmithKline’s Worldwide Business Development

/noticias.info/ London - GlaxoSmithKline (GSK) announces that Adrian Rawcliffe has been appointed Senior Vice President, Worldwide Business Development, Research & Development, effective immediately.

Rawcliffe had most recently served as Managing Partner and President, SR One Ltd, GSK’s venture-capital business. In his new role, he succeeds Moncef Slaoui, now chairman, R&D.

Rawcliffe will report to Dr. Slaoui and have global responsibility for all business-development activities including in-licensing, collaborations, and alliance management.

Dr. Slaoui commented, “Ad brings to our business-development function a proven capacity to work with our business partners, current and potential, in a way that maximizes value for all parties. He will be leading a function that is embedded in our R&D organization and committed to making our R&D strengths an advantage for our partners as well as for ourselves.”

At GSK, Rawcliffe has led teams executing a broad range of strategic transactions, including acquisitions, in-licenses, technology alliances, out-licenses, divestitures, joint ventures, and the formation of consortia.

He was appointed to his position at SR One in 2005. Previously, he served as Vice President, Genetics and Discovery Deal Structuring, concentrating on collaborations in early-stage drug development, and Vice President, Transactions and Ventures, leading a US-based transactions team whose activities encompassed both in-licensing and out-licensing.

Rawcliffe holds a BSc degree in Natural Sciences from the University of Durham, UK. He joined GSK in 1997 from Coopers and Lybrand, where he was a Chartered Accountant involved in a range of business-advisory activities.

His successor at SR One will be appointed in due course.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report on Form 20-F for 2005. notas_de_prensa_archivo